诺和诺德预警2026年销售额下滑

Core Viewpoint - Novo Nordisk (NVO) experienced a 5.7% decline in early trading due to pressures from price reductions in the U.S. and patent expirations in non-U.S. regions, with projected sales and operating profit expected to decrease by 5%-13% by 2026, despite the successful launch of the oral version of Wegovy [1][2]. Group 1 - Novo Nordisk's stock fell by 5.7% in early trading [1][2]. - The company faces challenges from U.S. price reductions and patent expirations in non-U.S. markets [1][2]. - Sales and operating profit are projected to decline by 5%-13% by 2026 [1][2]. Group 2 - The oral version of Wegovy is progressing well in its market launch [1][2].